Free shipping on orders over $79.00 USD

Discover the science behind every claim

JUMP TO:

OS-01 Peptide
OS-01 FACE
OS-01 EYE
OS-01 BODY
OS-01 FACE SPF (OS-01 SHIELD)
OS-01 BODY SPF
PREP
OS-01 HAIR

The OS-01 Peptide

Clinical Data

Skin barrier The OS-01 peptide improves skin's barrier function. Shown in a 12-week clinical study performed by a third party research organization with 22 participants, and measured with a vapometer. Effects of the peptide were isolated by evaluating the difference in barrier function between skin treated with OS-01 FACE versus an identical formulation without the OS-01 peptide (vehicle formulation). A significant improvement was observed between skin treated with OS-01 FACE versus the vehicle formulation. (Zonari, A., et al. Journal of Cosmetic Dermatology, 2024)
Hydration The OS-01 peptide improves skin hydration retention. Shown in a 12-week clinical study performed by a third party research organization with 22 participants, in which trans epidermal water loss (TEWL) was measured with a vapometer. Effects of the peptide were isolated by evaluating the difference in barrier function between skin treated with OS-01 FACE versus an identical formulation without the OS-01 peptide (vehicle formulation). A significant improvement was observed between skin treated with OS-01 FACE versus the vehicle formulation. (Zonari, A., et al. Journal of Cosmetic Dermatology, 2024)
Skin smoothness / texture The OS-01 peptide improves skin's texture. Shown in a 12-week clinical study performed by a third party research organization with 22 participants, and measured with an Antera 3D. Effects of the peptide were isolated by evaluating the difference in texture between skin treated with OS-01 FACE versus an identical formulation without the OS-01 peptide (vehicle formulation). A significant improvement was observed between skin treated with OS-01 FACE versus the vehicle formulation. (Zonari, A., et al. Journal of Cosmetic Dermatology, 2024)
Wrinkles The OS-01 peptide can reduce wrinkles. Shown in a 12-week clinical study performed by a third party research organization with 22 participants, and measured with an Antera 3D. Effects of the peptide were isolated by evaluating the difference in wrinkle indentation between skin treated with OS-01 FACE versus an identical formulation without the OS-01 peptide (vehicle formulation). A close to significant reduction (p=0.072) was observed between skin treated with OS-01 FACE versus the vehicle formulation. (Zonari, A., et al. Journal of Cosmetic Dermatology, 2024)
Radiance The OS-01 peptide can improve skin radiance. Shown in a 12-week clinical study performed by a third party research organization with 22 participants, and measured with VISIA imaging software. Effects of the peptide were isolated by evaluating the difference in skin radiance between skin treated with OS-01 FACE versus an identical formulation without the OS-01 peptide (vehicle formulation). A reduction (not statistically significant) was observed between skin treated with OS-01 FACE versus the vehicle formulation. (Zonari, A., et al. Journal of Cosmetic Dermatology, 2024)

 

Lab Data 

Age reversal The OS-01 peptide reverses skin’s biological age.
 Measured in lab studies on human skin samples using MolClock, OneSkin’s proprietary algorithm that predicts skin’s biological age. Skin treated with the OS-01 peptide displayed a significant decrease in skin’s biological age compared to skin with no treatment. (Zonari, A., et al. npj Aging, 2023) (Boroni, M. et al. Clinical Epigenetics, 2020) Note: In npj Aging publication,"Pep 14" = OS-01 peptide
Cellular senescence The OS-01 peptide reduces senescent burden / senescent cells / cellular senescence in skin.

The OS-01 peptide switches off senescent cells.

The OS-01 peptide most likely prevents pre-senescent cells from progressing to late-senescent cells, thereby reducing SASP-secreting cells and preventing the spread and accumulation of senescence in skin.
Shown in lab studies on human skin samples and/or cells by measuring the number of senescent cells via SA-Bgal staining, senescence biomarkers (CDKN2A/P16, CDKN1A, H2A.J), and SASP biomarkers (CXCL8 and IL-6). Skin treated with the OS-01 peptide displayed a significant decrease in all mentioned markers compared to skin with no treatment. (Zonari, A., et al. npj Aging, 2023) Note: In npj Aging publication,"Pep 14" = OS-01 peptide
Aging
The OS-01 peptide reduces key aging biomarkers in skin.
Shown in lab studies on human skin samples and/or cells by measuring key aging biomarkers, CDKN2A and B2M. Skin treated with the OS-01 peptide displayed a significant decrease compared to skin with no treatment. (Zonari, A., et al. npj Aging, 2023) Note: In npj Aging publication,"Pep 14" = OS-01 peptide
Repair The OS-01 peptide can support skin’s natural repair mechanisms.
Shown in lab studies on human skin cells by measuring key DNA damage biomarker, γH2A.x. Skin treated with the OS-01 peptide displayed a significant decrease compared to skin with no treatment. (Zonari, A., et al. npj Aging, 2023) Note: In npj Aging publication,"Pep 14" = OS-01 peptide
UV-induced aging The OS-01 peptide reduces/prevents UV-induced senescence in skin. Shown in lab studies on human skin cells by measuring the number of senescent cells via SA-Bgal staining before and after UVB exposure. Skin that was treated with the OS-01 peptide displayed a significant decrease (42.5% less UV-induced senescent cells) compared to skin that was not treated. (Zonari, A., et al. npj Aging, 2023) Note: In npj Aging publication,"Pep 14" = OS-01 peptide
The OS-01 peptide reduces/prevents UV-induced collagen degradation in skin. Shown in lab studies on human skin cells by measuring collagen degradation biomarker, MMP3, before and after UVB exposure. Skin treated with the OS-01 peptide displayed a decrease (not statistically significant) compared to skin with no treatment. (Zonari, A., et al. npj Aging, 2023) Note: In npj Aging publication,"Pep 14" = OS-01 peptide
Hyperpigmentation
 The OS-01 peptide reduces melanin deposits in human melanocytes. Melanin is visible as skin pigmentation, therefore the OS-01 peptide may help minimize the appearance of hyperpigmentation/sun spots/age spots, and improve skin tone.
Shown in lab studies on melanocytes (human pigment-producing skin cells) by measuring levels of intracellular and extracellular melanin after chemically-induced melanin production. Cells treated with the OS-01 peptide displayed less total melanin compared to cells with no treatment and compared to cells treated with retinoic acid and kojic acid. More information can be found here.
Cell proliferation / turnover
 The OS-01 peptide promotes increased cellular proliferation / turnover in skin.
Shown in lab studies on human skin samples and/or cells by measuring key cell proliferation biomarker, MKI67. Skin treated with the OS-01 peptide displayed a significant increase compared to skin with no treatment. (Zonari, A., et al. npj Aging, 2023) Note: In npj Aging publication,"Pep 14" = OS-01 peptide
Inflammation
 The OS-01 peptide reduces a key inflammation biomarker (IL-6) in skin.
Shown in lab studies on human skin samples by measuring key inflammation biomarker, IL-6. Skin treated with the OS-01 peptide displayed a significant decrease compared to skin with no treatment. (Zonari, A., et al. npj Aging, 2023) Note: In npj Aging publication,"Pep 14" = OS-01 peptide
Hyaluronic acid
 The OS-01 peptide increases hyaluronic acid production in skin.
Shown in lab studies on human skin samples by measuring key hyaluronic acid production biomarker, HAS2. Skin treated with the OS-01 peptide displayed a significant increase in the dermis compared to skin with no treatment. (Zonari, A., et al. npj Aging, 2023) Note: In npj Aging publication,"Pep 14" = OS-01 peptide
Collagen
 The OS-01 peptide increases collagen production in skin.
Shown in lab studies on human skin samples by measuring key collagen production biomarker, COL1A1. Skin treated with the OS-01 peptide displayed a significant increase compared to skin with no treatment. (Zonari, A., et al. npj Aging, 2023) Note: In npj Aging publication,"Pep 14" = OS-01 peptide
Keratin
 The OS-01 peptide increases keratin production in skin.
Shown in lab studies on human skin samples by measuring key keratin production biomarkers, KRT1 and KRT14. Skin treated with the OS-01 peptide displayed significant increases compared to skin with no treatment. (Zonari, A., et al. npj Aging, 2023) Note: In npj Aging publication,"Pep 14" = OS-01 peptide
Epidermal thickness
The OS-01 peptide promotes an increase in epidermal thickness (of up to +28%).
Shown in lab studies on human skin samples by measuring epidermal thickness of histology images. Skin treated with the OS-01 peptide displayed a significant increase compared to skin with no treatment. (Zonari, A., et al. npj Aging, 2023) Increase of +28% was measured on human skin sample from a 55 year old donor treated with the OS-01 peptide. Data was measured in triplicate. Note: In npj Aging publication,"Pep 14" = OS-01 peptide
Skin barrier
 The OS-01 peptide likely improves skin’s barrier function by promoting increased epidermal thickness.
Shown in lab studies on human skin samples by measuring epidermal thickness of histology images. Skin treated with the OS-01 peptide displayed a significant increase compared to skin with no treatment. (Zonari, A., et al. npj Aging, 2023) Epidermal thickness is known to be a key contributor to barrier function. Note: In npj Aging publication,"Pep 14" = OS-01 peptide
Senescence in hair
 The OS-01 peptide significantly reduces a key senescence biomarker, CDKN1A (p21), in stressed hair follicle cells.
Shown in lab studies on ORSCs (hair follicle cells) by measuring the change in CDKN1A (p21) mRNA. Cells were treated with corticotropin-releasing hormone (CRH) alone or in combination with the OS-01 peptide. After 72 hours, cells treated with the OS-01 peptide + CRH showed significantly lower CDKN1A (p21) levels compared to those treated with CRH alone (*p < 0.05).

 

OS-01 FACE

Clinical Data

Skin barrier OS-01 FACE improves skin barrier function by an average of +15-19%. Shown in a 12-week clinical study performed by a third party research organization with 22 participants, and measured with a vapometer. A significant improvement of an average of +19% was observed in skin treated with OS-01 FACE for 4 weeks versus baseline, and a significant improvement of an average of +15% was observed in skin treated with OS-01 FACE for 12 weeks versus baseline. (Zonari, A., et al. Journal of Cosmetic Dermatology, 2024)
Hydration OS-01 FACE improves skin hydration retention. Shown in a 12-week clinical study performed by a third party research organization with 22 participants, in which trans epidermal water loss (TEWL) was measured with a vapometer. A significant improvement was observed in skin treated with OS-01 FACE for 12 weeks versus baseline. (Zonari, A., et al. Journal of Cosmetic Dermatology, 2024)
Elasticity OS-01 FACE improves skin elasticity (shown in 90% of users). Shown in a 12-week clinical study performed by a third party research organization with 22 participants, and analyzed via double-blind expert clinical grader evaluation. An improvement was observed in 90% of participants in skin treated with OS-01 FACE for 12 weeks versus baseline. (Zonari, A., et al. Journal of Cosmetic Dermatology, 2024)
Tone, radiance, pores, firmness OS-01 FACE improves skin evenness, radiance, pores and firmness (shown in 95.5% of users) Shown in a 12-week clinical study performed by a third party research organization with 22 participants, and analyzed via double-blind expert clinical grader evaluation. An improvement was observed in 95.5% of participants in skin treated with OS-01 FACE for 6-12 weeks versus baseline. (Zonari, A., et al. Journal of Cosmetic Dermatology, 2024, supporting information)
Fine lines + wrinkles OS-01 FACE reduces the appearance of fine lines and wrinkles (shown in 86% of users). Shown in a 12-week clinical study performed by a third party research organization with 22 participants, and analyzed via double-blind expert clinical grader evaluation. An improvement was observed in 86% of participants in skin treated with OS-01 FACE for 12 weeks versus baseline. (Zonari, A., et al. Journal of Cosmetic Dermatology, 2024, supporting information)
Overall appearance + smoothness OS-01 FACE improves skin smoothness and overall appearance (shown in 100% of users). Shown in a 12-week clinical study performed by a third party research organization with 22 participants, and analyzed via double-blind expert clinical grader evaluation. An improvement was observed in 100% of participants in skin treated with OS-01 FACE for 12 weeks versus baseline. (Zonari, A., et al. Journal of Cosmetic Dermatology, 2024, supporting information)
Hyperpigmentation 68.4% of users agree that their dark spots (hyperpigmentation) improved after using OS-01 FACE. Shown in a 6-week clinical study performed by a third party research organization with 38 participants who self-reported improvements in dark spots (lightening of hyperpigmentation) after using OS-01 FACE compared to baseline.
Eye bags 68.4% of users agree that their eye bags improved after using OS-01 FACE. Shown in a 6-week clinical study performed by a third party research organization with 38 participants who self-reported improvements in eye bags after using OS-01 FACE compared to baseline.
Improvement in skin issues such as acne and redness 51.8% of participants agree issues in their skin such as acne and redness improved after using OS-01 FACE Shown in a 6-week clinical study performed by a third party research organization with 29 participants who self-reported improvements in existing skin issues after using OS-01 FACE compared to baseline.
Skin microbiome OS-01 FACE is clinically validated to support skin’s microbiome. Shown in a 6-week clinical study performed by a third party research organization (HelloBiome) with 38 participants who collected samples of their facial skin microbiome before and after treatment with OS-01 FACE for 6 weeks. Using next generation sequencing and existing research, HelloBiome determined that OS-01 FACE supports skin’s microbiome because:
  • Participants displayed a significant positive shift of the microbiome grade after treatment compared to baseline
  • No significant changes in the ratio of bacteria to fungi were detected after treatment compared to baseline
To learn more, click here.
Non-comedogenic OS-01 FACE is non-comedogenic. Show in a four-week single-blind clinical study with 33 participants assessing the comedogenic potential of OS-01 FACE, OS-01 EYE, OS-01 FACE SPF (OS-01 SHIELD), and OS-01 BODY SPF by means of repeated occlusive cutaneous patch applications and follicular biopsy procedure. The positive control (lanolin) showed significantly higher follicular biopsy scores compared to the test products (p<0.05). When compared to the negative control (untreated site), there were no statistically significant changes in skin treated with the test products, clinically proving that the test products are non-comedogenic.
Sensitive skin OS-01 FACE is Dermatologically Tested and Safe for Sensitive Skin. Shown in a clinical study with 54 healthy volunteers by means of repeated cutaneous occlusive patch applications, after which there were no questionable reactions observed.
Eczema OS-01 FACE has been awarded the National Eczema Association Seal of AcceptanceTM by the National Eczema Association (NEA). NEA awards the Seal to products that are deemed suitable for people with eczema or sensitive skin, based on sensitivity, toxicity, and ingredient testing data. To learn more about the Seal, click here. You can find OS-01 FACE on the NEA Seal Product Directory here. RIPT study was performed on 108 participants.

 

Lab Data

Epidermal thickness OS-01 FACE promotes an increase in epidermal thickness (of +23% on average). Shown in lab studies on human skin samples by measuring epidermal thickness of histology images. Skin treated with OS-01 FACE displayed a significant increase (average +23%) compared to skin with no treatment. (Zonari, A., et al. npj Aging, 2023, supplementary information) Note: In npj Aging publication, "Topical Pep 14" = OS-01 FACE
Aging OS-01 FACE reduces key aging biomarkers in skin. Shown in lab studies on human skin samples by measuring key aging biomarkers, CDKN2A and B2M. Skin treated with OS-01 FACE displayed a significant decrease compared to skin with no treatment. (Zonari, A., et al. npj Aging, 2023, supplementary information) Note: In npj Aging publication, "Topical Pep 14" = OS-01 FACE
Cell proliferation / turnover OS-01 FACE promotes increased cellular proliferation / turnover in skin. Shown in lab studies on human skin samples by measuring key cell proliferation biomarkers, MKI67 and Ki-67. Skin treated with OS-01 FACE displayed significant increases compared to skin with no treatment. (Zonari, A., et al. npj Aging, 2023) Note: In npj Aging publication, "Topical Pep 14" = OS-01 FACE
Collagen OS-01 FACE increases collagen production in skin. Shown in lab studies on human skin samples by measuring key collagen production biomarker, COL1A1. Skin treated with OS-01 FACE displayed a significant increase compared to skin with no treatment. (Zonari, A., et al. npj Aging, 2023, supplementary information) Note: In npj Aging publication, "Topical Pep 14" = OS-01 FACE
OS-01 FACE can increase collagen production in skin by up to 1.4x (+40%). Shown in lab studies on ex vivo human skin sample (70 yr) by analyzing levels of collagen in the dermis. Skin treated with OS-01 FACE displayed an increase (not statistically significant) compared to skin with no treatment. Data was measured in triplicate.
OS-01 FACE vs retinol
(collagen)		 OS-01 FACE and retinol both increase collagen production at similar levels in skin. Shown in lab studies on human skin samples by measuring key collagen production biomarker, COL1A1, in skin treated with nothing, OS-01 FACE, or 1% topical retinol for 5 days. Skin treated with OS-01 FACE and retinol both displayed similar and significant increases compared to skin with no treatment. (Zonari, A., et al. npj Aging, 2023, supplementary information) Note: In npj Aging publication, "Topical Pep 14" = OS-01 FACE
OS-01 FACE vs retinol
(aging/senescence)		 Retinol increases a key aging & senescence biomarker in skin, while OS-01 FACE does not. Shown in lab studies on human skin samples by measuring key aging & senescence biomarker, CDKN2A, in skin treated with nothing, OS-01 FACE, or 1% topical retinol for 5 days. Skin treated with retinol displayed a significant increase compared to skin treated with OS-01 FACE and skin with no treatment, while skin treated with OS-01 FACE displayed no change compared to skin with no treatment. (Zonari, A., et al. npj Aging, 2023, supplementary information) Note: In npj Aging publication, "Topical Pep 14" = OS-01 FACE
OS-01 FACE vs retinol
(cell proliferation and epidermal thickness)		 OS-01 FACE increases a key cell proliferation biomarker in the dermis, and increases skin’s epidermal thickness, while retinol does not.

Shown in lab studies on human skin samples by measuring key cell proliferation biomarker, MKi67, and epidermal thickness in skin treated with nothing, OS-01 FACE, or 1% topical retinol for 5 days. Skin treated with OS-01 FACE displayed a significant increase compared to skin with no treatment, while skin treated with retinol displayed no change compared to skin with no treatment. (Zonari, A., et al. npj Aging, 2023, supplementary information)

Note: In npj Aging publication, "Topical Pep 14" = OS-01 FACENote: Skin that had been treated with OS-01 FACE and retinol both displayed significant increases in cell proliferation biomarker, MKi67, in the epidermis compared to skin with no treatment. (Zonari, A., et al. npj Aging, 2023, supplementary information) These results represent acute responses to the products and may not reflect long-term results.

 

OS-01 EYE

Clinical Data

Hydration OS-01 EYE improves skin hydration. (Shown in 87.5% of users with an average improvement of +32.49%.). Shown in a 12-week clinical study performed by a third party research organization with 22 participants, in which participants self-reported results and skin hydration was measured with a corneometer. A significant improvement of avg +32.49% was measured in 87.5% of participants from corneometer measurements in skin treated with OS-01 EYE for 12 weeks versus baseline. (Zonari, A., et al. International Journal of Cosmetic Science, 2025)
Elasticity OS-01 EYE improves skin elasticity. (Shown in 86% of users with an average improvement of +25.58%, and observed by 82% of users.) Shown in a 12-week clinical study performed by a third party research organization with 22 participants, in which elasticity was measured with a cutometer. A significant improvement of avg +25.58% was measured in 86% of participants in skin treated with OS-01 EYE for 12 weeks versus baseline. Additionally, 82% of users observed an improvement. (Zonari, A., et al. International Journal of Cosmetic Science, 2025)
Firmness OS-01 EYE improves skin firmness. (Observed by 82% of users and shown in 72.73% of users with an average improvement of +10.19%.) Shown in a 12-week clinical study performed by a third party research organization with 22 participants, in which participants self-reported results and firmness was measured with a cutometer. 82% respondents reported an improvement in skin firmness/elasticity and a significant improvement of avg +10.19% was measured in 72.73% of participants in skin treated with OS-01 EYE for 12 weeks versus baseline. (Zonari, A., et al. International Journal of Cosmetic Science, 2025)
Skin barrier OS-01 EYE improves skin barrier function by an average of +17.33%. Shown in a 12-week clinical study performed by a third party research organization with 22 participants, in which trans-epidermal water loss (TEWL) was measured with a vapometer. A significant improvement of an average of +17.33% was measured in 69.57% of participants in skin treated with OS-01 EYE for 12 weeks versus baseline. (Zonari, A., et al. International Journal of Cosmetic Science, 2025)
Tone + texture OS-01 EYE improves skin tone and texture. (Observed by 95.46% of users.) Shown in a 12-week clinical study performed by a third party research organization with 22 participants, in which 95.46% of respondents reported an improvement in skin tone and texture in skin treated with OS-01 EYE for 4 weeks versus baseline. (Zonari, A., et al. International Journal of Cosmetic Science, 2025)
Radiance OS-01 EYE improves skin radiance. (Observed by 90.91% of users.) Shown in a 12-week clinical study performed by a third party research organization with 22 participants, in which 90.91% of respondents reported an improvement in skin radiance in skin treated with OS-01 EYE for 4 weeks versus baseline. (Zonari, A., et al. International Journal of Cosmetic Science, 2025)
Hyperpigmentation OS-01 EYE improves hyperpigmentation. (Observed by 81.82% of users.) Shown in a 12-week clinical study performed by a third party research organization with 22 participants, in which 81.82% of respondents reported an improvement in skin radiance in skin treated with OS-01 EYE for 4 weeks versus baseline. (Zonari, A., et al. International Journal of Cosmetic Science, 2025)
Puffiness OS-01 EYE reduces under-eye puffiness. (Observed by 77% of users and noted by blinded expert grader evaluators.) Shown in a 12-week clinical study performed by a third party research organization with 22 participants, in which 77% of respondents reported an improvement in eye puffiness, which was also observed to a statistically significant level in 59.09% by blinded expert graders, in skin treated with OS-01 EYE for 12 weeks versus baseline. (Zonari, A., et al. International Journal of Cosmetic Science, 2025)
Fine lines & wrinkles OS-01 EYE reduces the appearance of fine lines and wrinkles, according to blinded expert grader evaluators. Shown in a 12-week clinical study performed by a third party research organization with 22 participants, in which blinded expert clinical graders evaluated VISIA-CR photographs of participants treated with OS-01 EYE for 12 weeks versus baseline. A significant improvement was observed at week 12 in 59.09% of the participants. (Zonari, A., et al. International Journal of Cosmetic Science, 2025)
Dark circles OS-01 EYE reduces the appearance of dark circles, according to blinded expert grader evaluators. Shown in a 12-week clinical study performed by a third party research organization with 22 participants, in which blinded expert clinical graders evaluated VISIA-CR photographs of participants treated with OS-01 EYE for 12 weeks versus baseline. A significant improvement was observed at week 12 in 50% of the participants. (Zonari, A., et al. International Journal of Cosmetic Science, 2025)
Overall appearance OS-01 EYE improves skin’s overall appearance. (Observed by 95.46% of users.) Shown in a 12-week clinical study performed by a third party research organization with 22 participants, in which 95.46% of respondents reported an improvement in overall appearance in skin treated with OS-01 EYE for 12 weeks versus baseline. (Zonari, A., et al. International Journal of Cosmetic Science, 2025)
Non-comedogenic OS-01 EYE is non-comedogenic. Show in a four-week single-blind clinical study with 33 participants assessing the comedogenic potential of OS-01 FACE, OS-01 EYE, OS-01 FACE SPF (OS-01 SHIELD), and OS-01 BODY SPF by means of repeated occlusive cutaneous patch applications and follicular biopsy procedure. The positive control (lanolin) showed significantly higher follicular biopsy scores compared to the test products (p<0.05). When compared to the negative control (untreated site), there were no statistically significant changes in skin treated with the test products, clinically proving that the test products are non-comedogenic.
Sensitive skin OS-01 EYE is Dermatologically Tested and Safe for Sensitive Skin. Show in a clinical study with 54 healthy volunteers by means of repeated cutaneous occlusive patch applications, after which there were no questionable reactions observed.
Eczema OS-01 EYE has been awarded the National Eczema Association Seal of AcceptanceTM by the National Eczema Association (NEA). NEA awards the Seal to products that are deemed suitable for people with eczema or sensitive skin, based on sensitivity, toxicity, and ingredient testing data. To learn more about the Seal, click here. You can find OS-01 EYE on the NEA Seal Product Directory here. RIPT study was performed on 108 participants.

 

Lab Data

Collagen OS-01 EYE improves collagen production and reduces collagen degradation in skin. Shown in lab studies on ex vivo human eyelid skin samples (42, 59, 84 yr) by measuring key collagen production biomarker, COL1A1, and key collagen degradation biomarker, MMP1. Skin treated with OS-01 EYE displayed a close to significant (p=0.11) increase in COL1A1 and a significant decrease in MMP1 (p=0.0445) compared to skin with no treatment.
OS-01 EYE increases collagen by up to 2.3x (+130%). Shown in lab studies on ex vivo human eyelid skin samples (70 yr) by analyzing levels of collagen in skin treated with OS-01 EYE compared to no treatment. Skin treated with OS-01 EYE displayed a significant increase compared to skin with no treatment. (**p < 0.01) Data was measured in triplicate.
Cellular senescence OS-01 EYE reduces a key cellular senescence and aging biomarker in skin. Shown in lab studies on ex vivo human eyelid skin samples (42, 59, 84 yr) by measuring key senescence and aging biomarker, CDKN2A. Skin treated with OS-01 EYE displayed a significant decrease in CDKN2A compared to skin with no treatment.
Inflammation OS-01 EYE reduces a key inflammation biomarker in skin. Shown in lab studies on ex vivo human eyelid skin samples (42, 59, 84 yr) by measuring key inflammation biomarker, IL-8. Skin treated with OS-01 EYE displayed a significant decrease in IL-8 compared to skin with no treatment.

 

OS-01 BODY

Clinical Data

Hydration OS-01 BODY improves skin hydration. (Observed by 93% of users and shown in a significant number of users, with and average improvement of +38.34% on forearm skin and +38.39% on upper arm skin.) Shown in a 12-week clinical study performed by a third party research organization with 27 participants, in which participants self-reported results and skin hydration was measured with a corneometer in skin treated with OS-01 BODY 12 weeks versus baseline. 93% of respondents reported an improvement in skin hydration. Improvement in skin hydration was measured in a significant number of participants, with an avg improvement of +38.34% on forearm skin and +38.39% on the upper arm skin. (OneSkin manuscript in process of publication, explore the study here)
Skin barrier OS-01 BODY improves skin barrier. (Average +41.49% forearm; average +34.73% upper arm.) Shown in a 12-week clinical study performed by a third party research organization with 27 participants, in which trans-epidermal water loss (TEWL) was measured with a tewameter in skin treated with OS-01 BODY 12 weeks versus baseline. Improvement in barrier function was measured in a significant number of participants, with an avg improvement of +41.49% on forearm skin and +34.73% on the upper arm skin. (OneSkin manuscript in process of publication, explore the study here)
Texture OS-01 BODY improves skin texture. (Observed by 70% of users.) Shown in a 12-week clinical study performed by a third party research organization with 27 participants, in which 70% of participants reported improved skin texture after using OS-01 BODY for 12 weeks compared to baseline. (OneSkin manuscript in process of peer-reviewed publication, explore the study here)
General appearance OS-01 BODY improves skin’s general appearance. (Observed by 72% of users.) Shown in a 12-week clinical study performed by a third party research organization with 27 participants, in which 72% of participants reported an improvement in skin’s general appearance after using OS-01 BODY for 12 weeks compared to baseline. (OneSkin manuscript in process of peer-reviewed publication, explore the study here)
Inflammation OS-01 BODY may help reduce circulating/systemic inflammation. Shown in a 12-week clinical study performed by a third party research organization with 27 participants, in which blood samples of participants were collected at baseline and after 12 weeks of using OS-01 BODY. Participants experienced a general decrease in cytokine levels and a significant decrease in circulating IL-8 compared to baseline. (OneSkin manuscript in process of peer-reviewed publication, explore the study here)
Biological age OS-01 BODY can pause biological aging. Shown in a 12-week clinical study performed by a third party research organization with 52 participants, in which blood samples of participants were collected at baseline and after 12 weeks of using OS-01 BODY or a control formulation (an average drugstore moisturizer). The biological age of participants was measured using GlycanAge at baseline and after 12 weeks of using OS-01 BODY or the control formulation. The biological age of participants using OS-01 BODY (n=27) did not change, while the biological age of participants using the control formula (n=25) increased compared to baseline. (OneSkin manuscript in process of peer-reviewed publication, explore the study here)
OS-01 Peptide penetration into bloodstream The OS-01 peptide does not accumulate in the bloodstream when applied topically. Shown in a 12-week clinical study performed by a third party research organization with 52 participants, in which blood samples of participants were collected at baseline and after 12 weeks of using OS-01 BODY daily. Using mass spectroscopy and no peptide was detected in plasma samples after 12 weeks. (OneSkin manuscript in process of peer-reviewed publication, explore the study here)
Sensitive skin OS-01 BODY is Dermatologically Tested and Safe for Sensitive Skin. Show in a clinical study with 54 healthy volunteers by means of repeated cutaneous occlusive patch applications, after which there were no questionable reactions observed.
Eczema OS-01 BODY has been awarded the National Eczema Association Seal of AcceptanceTM by the National Eczema Association (NEA).

NEA awards the Seal to products that are deemed suitable for people with eczema or sensitive skin, based on sensitivity, toxicity, and ingredient testing data. To learn more about the Seal, click here. You can find OS-01 BODY on the NEA Seal Product Directory here. RIPT study was performed on 114 participants.

 

Lab Data

Epidermal thickness OS-01 BODY promotes an increase in epidermal thickness (of up to 40%). Shown in lab studies on ex vivo human skin samples (44 yr) by measuring epidermal thickness of histology images. Skin treated with OS-01 BODY displayed a significant increase of +40% compared to skin with no treatment. Data was measured in triplicate.

 

OS-01 FACE SPF (OS-01 SHIELD)

Clinical Data

UVA + UVB protection Broad Spectrum SPF 30+ Passed the Broad Spectrum Test in 21 CFR 201.327(j)
PA+++ Passed the In-Vivo UVA-PF Determination Study #23-944 Utilizing ISO 24442-2022(E)
Feel / visual benefits Skin feels moisturized after using OS-01 FACE SPF (91% of users agree)

Skin feels nourished after using OS-01 FACE SPF (87% of users agree)

OS-01 FACE SPF spreads easily (80% of users agree)

Skin feels more hydrated after using OS-01 FACE SPF (78% of users agree)

OS-01 FACE SPF blends seamlessly (76% of users agree)

OS-01 FACE SPF is lightweight (76% of users agree)

OS-01 FACE SPF absorbs easily (73% of users agree)

Skin feels smoother after using OS-01 FACE SPF (71% of users agree)

Skin appears more radiant after using OS-01 FACE SPF(71% of users agree)

OS-01 FACE SPF sits well under makeup (71% of users agree)		 Shown in a 30 day consumer perception study with 50 participants performed by a third party research organization. Participants self-reported the effects of OS-01 FACE SPF (untinted) compared to baseline.
Blending capability with different skin tones OS-01 FACE SPF (Tinted):
  • Type I-II (n=28):
    • 78% agreed product matched seamlessly
    • 14% thought product was too dark
  • Type III-IV (n=4):
    • 75% agreed product matched seamlessly
    • 25% thought product was too dark
  • Types V-VI (n=6):
    • 33% thought tint was too light
    • 66% agreed tint matched seamlessly
OS-01 FACE SPF (Untinted):
  • Type I-II (n=16):
    • 69% agreed no white cast
    • 18% reported a white cast
  • Types III-IV (n=7):
    • 100% agreed no white cast
  • Types V-VI (n=8):
    • 37.5% agreed no white cast
    • 37.5% reported a white cast
 Based on a one week beta test (consumer perception) study, performed with 31 (tinted) and 38 (non-tinted) randomly selected participants, in which participants self-reported their results after using OS-01 FACE SPF at least once daily for one week.
Sunburn OS-01 FACE SPF is more effective at protecting against UV-induced erythema (sunburn) compared to a top dermatologist recommended brand. Shown in a clinical study performed by a third party research organization with 30 participants, measuring erythema levels on skin protected with OS-01 FACE SPF versus a top dermatologist recommended brand before and 24 hours after UV exposure.
UV-induced pigmentation OS-01 FACE SPF is more effective at protecting against UV-induced pigmentation compared to a top dermatologist recommended brand. Shown in a clinical study performed by a third party research organization with 30 participants, measuring pigmentation levels on skin protected with OS-01 FACE SPF versus a top dermatologist recommended brand before and 24 hours after UV exposure.
Non-comedogenic OS-01 FACE SPF is non-comedogenic. Show in a four-week single-blind clinical study with 33 participants assessing the comedogenic potential of OS-01 FACE, OS-01 EYE, OS-01 FACE SPF (OS-01 SHIELD), and OS-01 BODY SPF by means of repeated occlusive cutaneous patch applications and follicular biopsy procedure. The positive control (lanolin) showed significantly higher follicular biopsy scores compared to the test products (p<0.05). When compared to the negative control (untreated site), there were no statistically significant changes in skin treated with the test products, clinically proving that the test products are non-comedogenic.
Sensitive skin OS-01 FACE SPF is Dermatologically Tested and Safe for Sensitive Skin. Show in a clinical study with 54 healthy volunteers by means of repeated cutaneous occlusive patch applications, after which there were no questionable reactions observed.
Eczema OS-01 FACE SPF has been awarded the National Eczema Association Seal of AcceptanceTM by the National Eczema Association (NEA). NEA awards the Seal to products that are deemed suitable for people with eczema or sensitive skin, based on sensitivity, toxicity, and ingredient testing data. To learn more about the Seal, click here. You can find OS-01 FACE SPF on the NEA Seal Product Directory here. RIPT study was performed on 104 participants.

 

Lab Data

Cellular senescence OS-01 FACE SPF protects against UV-induced cellular senescence (superior to regular sunscreen). Shown in lab studies by measuring a key senescence biomarker (P16) on ex vivo human skin samples (31y and 41y) treated with nothing (No Sunscreen), regular sunscreen (average drugstore sunscreen), or OS-01 FACE SPF (tinted & non-tinted), then exposed to UVB radiation. Skin treated with OS-01 FACE SPF displayed significantly lower levels of P16 compared to skin with no treatment and skin treated with regular sunscreen.
OS-01 FACE SPF reduces cellular senescence in skin. Shown in lab studies by measuring a key senescence biomarker (P16) on ex vivo human skin samples treated with nothing or OS-01 FACE SPF. Skin treated with OS-01 FACE SPF displayed significantly lower levels of P16 compared to skin with no treatment.
Inflammation OS-01 FACE SPF protects against UV-induced inflammation (superior to regular sunscreen). Shown in lab studies by measuring a key inflammation biomarker (IL-6) on ex vivo human skin samples (31y and 41y) treated with nothing (No Sunscreen), regular sunscreen (average drugstore sunscreen), or OS-01 FACE SPF (tinted & non-tinted), then exposed to UVB radiation. Skin treated with OS-01 FACE SPF displayed significantly lower levels of IL-6 compared to skin with no treatment and skin treated with regular sunscreen.
Past aging OS-01 FACE SPF can reduce effects of past aging. Shown in lab studies by measuring a key senescence biomarker (P16) and inflammation biomarker (IL-8) on ex vivo human skin samples treated with nothing or OS-01 FACE SPF. Skin treated with OS-01 FACE SPF displayed significantly lower levels of P16 and IL-8 compared to skin with no treatment.
Antioxidant power / free radicals OS-01 FACE SPF scavenges free radicals 4x more effectively than a leading "anti-aging" antioxidant SPF moisturizer. Shown in lab studies utilizing a chemical probe with a stable radical that changes color when that radical is scavenged to measure the antioxidant capacity OS-01 FACE SPF versus a leading "anti-aging" antioxidant SPF moisturizer.
OS-01 FACE SPF performs similarly to common vitamin C serum at neutralizing free radicals. Shown in lab studies by measuring levels of free radical scavenging for common vitamin C serums (popular $90 and $50 vitamin C serums) and OS-01 FACE SPF using a DPPH assay. More information can be found here.

 

OS-01 BODY SPF

Clinical Data

Broad spectrum Broad Spectrum Passed the Broad Spectrum MO20.90 #23-1921
UVB protection SPF 30+ FDA 2021 Static SPF #24-1391 for SPF30+
UVA protection PA+++ Shown in a 30 day consumer perception study with 50 participants performed by a third party research organization. Participants self-reported the effects of OS-01 FACE SPF (untinted) compared to baseline.
Water resistance Water Resistant (80 minutes) Passed the FDA 2021 M020.80 SPF 80 Min Water Resistance #23-1844 test for SPF30+ 80min Water resistant
Non-comedogenic OS-01 BODY SPF is non-comedogenic. Show in a four-week single-blind clinical study with 33 participants assessing the comedogenic potential of OS-01 FACE, OS-01 EYE, OS-01 FACE SPF (OS-01 SHIELD), and OS-01 BODY SPF by means of repeated occlusive cutaneous patch applications and follicular biopsy procedure. The positive control (lanolin) showed significantly higher follicular biopsy scores compared to the test products (p<0.05). When compared to the negative control (untreated site), there were no statistically significant changes in skin treated with the test products, clinically proving that the test products are non-comedogenic.
Feel / visual benefits 100% of users agree OS-01 BODY SPF applies evenly and smooth.

96.7% of users agree OS-01 BODY SPF feels light and weightless on their skin.

76.6% of users agree their skin feels instantly hydrated upon application.

83.3% of users agree OS-01 BODY SPF does not leave their skin oily/greasy.

93.3% of users agree OS-01 BODY SPF does not clog their pores.

93.3% of users agree OS-01 BODY SPF blends seamlessly with their skin tone.

(Of Type I - IV skin tones (n=20), 100% of users agree OS-01 BODY SPF blends seamlessly with their skin tone)

(Of Type V - VI skin tones (n=10), 80% of users agree OS-01 BODY SPF blends seamlessly with their skin tone)

85.2% of users agree the product worked well with the rest of their skin routine.		 Shown in a one week beta test (consumer perception study) performed with 30 participants
Sensitive skin OS-01 BODY SPF is Dermatologically Tested and Safe for Sensitive Skin. Show in a clinical study with 54 healthy volunteers by means of repeated cutaneous occlusive patch applications, after which there were no questionable reactions observed.
Sunburn OS-01 BODY SPF is more effective at protecting against UV-induced erythema (sunburn) compared to a market-leading mineral sunscreen and a top dermatologist recommended anti-aging sunscreen. Shown in a clinical study performed by a third party research organization with 26 participants, measuring erythema levels with a Chromameter on skin protected with OS-01 BODY SPF versus a popular mineral sunscreen and a top dermatologist recommended anti-aging sunscreen before and 24 hours after UV exposure.
UV-induced pigmentation OS-01 BODY SPF is more effective at protecting against UV-induced pigmentation compared to a market-leading mineral sunscreen and a top dermatologist recommended anti-aging sunscreen. Shown in a clinical study performed by a third party research organization with 26 participants, measuring pigmentation levels with a Chromameter on skin protected with OS-01 BODY SPF versus a popular mineral sunscreen and a top dermatologist recommended anti-aging sunscreen before and 24 hours after UV exposure.
Eczema OS-01 BODY SPF has been awarded the National Eczema Association Seal of AcceptanceTM by the National Eczema Association (NEA). NEA awards the Seal to products that are deemed suitable for people with eczema or sensitive skin, based on sensitivity, toxicity, and ingredient testing data. To learn more about the Seal, click here. You can find OS-01 FACE SPF on the NEA Seal Product Directory here. RIPT study was performed on 108 participants.

 

Lab Data

UV-induced collagen degradation OS-01 BODY SPF protects skin from UV-induced collagen degradation. Shown lab studies by measuring collagen density in ex vivo human skin samples (41, 59, and 66y) that were treated with nothing (No Treatment, control) or OS-01 BODY SPF then exposed to UV radiation. Collagen density was analyzed after 24 hours. Collagen density of No Treatment + UVB decreased by 16.53%** compared to control. Collagen density of OS-01 BODY SPF + UVB increased by 8.9% compared to control. Collagen density of OS-01 BODY SPF + UVB increased by 30%*** compared to no treatment + UVB. (**p<0.01; ****p<0.0001) Discover more here.
Effects of UV aging OS-01 BODY SPF reduces the effects of UV aging, including biomarkers associated with senescence and aging, inflammation, and collagen and hyaluronic acid breakdown. Shown in lab studies by measuring levels of key biomarkers associated with senescence/aging (P16), inflammation (IL-8), hyaluronic acid breakdown (HYAL1) and collagen breakdown (MMP1) in ex vivo human skin samples (41y and 59y) that were treated with nothing (No Treatment) or OS-01 BODY SPF, then exposed to UV radiation. Biomarkers were analyzed after 24 hours. P16, IL-8, and HYAL1 significantly decreased in skin treated with OS-01 BODY SPF compared to No Treatment + UVB (*p<0.05, **p<0.01). The decrease in MMP-1 was not statistically significant. Discover more here.
Antioxidant power OS-01 BODY SPF offers superior antioxidant power compared to other “anti-aging” SPFs containing antioxidants. Antioxidant capacity of OS-01 BODY and commonly used “anti-aging” SPFs with antioxidants were measured using a DPPH assay. Measured four separate times. Discover more here.

 

PREP

Clinical Data

Sensitive skin PREP is Dermatologically Tested and Safe for Sensitive Skin. Show in a clinical study with 54 healthy volunteers by means of repeated cutaneous occlusive patch applications, after which there were no questionable reactions observed.
Eczema PREP has been awarded the National Eczema Association Seal of AcceptanceTM by the National Eczema Association (NEA). NEA awards the Seal to products that are deemed suitable for people with eczema or sensitive skin, based on sensitivity, toxicity, and ingredient testing data. To learn more about the Seal, click here. You can find PREP on the NEA Seal Product Directory here. RIPT study was performed on 108 participants.

 

Lab Data

OS-01 peptide penetration PREP can improve peptide penetration by up to 2x. Shown in lab studies on ex vivo human skin samples (54 yr) by comparing the amount of OS-01 peptide present in the dermis layer before and after treatment with PREP + OS-01 FACE vs OS-01 FACE alone. Data measured in triplicate.
Hydration PREP can enhance the hydration effects of OS-01 FACE. Shown in lab studies on ex vivo human skin samples (46 yr) by comparing levels of key skin hydration biomarker (AQP3) before and after treatment with PREP + OS-01 FACE vs OS-01 FACE alone. Data measured in triplicate.

 

OS-01 HAIR

Clinical Data

Hair density

OS-01 HAIR significantly increases hair density. (Shown in 86.67% of participants with an average improvement of 39.62% after 6 months.)

70% of users experienced an increase in hair density within 3 months. (Shown in 70% of participants with an average improvement of 9.97% after 3 months.)

Shown in 6 month double-blind, independent, third-party clinical study with 30 participants using OS-01 HAIR twice daily and dermarolling once daily. Hair parameters were measured using HairMetrix® clinical photography, Trichoscopy and Phototrichogram.

- After 3 months, 70% of participants experienced a 9.97% average decrease in inter follicular mean distance. ( **p < 0.01)

- After 6 months, 86.67% of participants experienced a 39.62% average increase in hair count per cm2. (****p < 0.0001)

- Participants saw a significant increase in hair count per cm2 between 3 and 6 months (**p < 0.01)

6 out of 7 (85.71%) men experienced an average increase of 34.86% in hair density after 6 months of using OS-01 HAIR.

Shown in 6 month double-blind, independent, third-party clinical study with 7 male participants using OS-01 HAIR twice daily and dermarolling once daily. Hair parameters measured using HairMetrix® clinical photography, Trichoscopy and Phototrichogram. After 6 months, 85.71% of male participants experienced a 34.86% average increase in hair count per cm2. (*p < 0.05)
Hair thickness OS-01 HAIR significantly increases hair thickness. (Shown in 83.33% of participants with an average improvement of 42.58% after 6 months)

Shown in 6 month double-blind, independent, third-party clinical study with 30 participants using OS-01 HAIR twice daily and dermarolling once daily. Hair parameters were measured using HairMetrix® clinical photography, Trichoscopy and Phototrichogram.

- After 6 months, 83.33% of participants experienced a 42.58% average increase in hair thickness (sum of hair widths). (****p < 0.0001)

- Participants saw a significant increase in hair thickness (sum of hair widths) between 3 and 6 months (**p < 0.01)

100% of men experienced an average increase of 36.68% in hair thickness after 6 months of using OS-01 HAIR.

6 out of 7 men experienced an average increase of 28.42% increase in hair thickness within 3 months.

Shown in 6 month double-blind, independent, third-party clinical study with 7 male participants using OS-01 HAIR twice daily and dermarolling once daily. Hair parameters measured using HairMetrix® clinical photography, Trichoscopy and Phototrichogram.

- After 3 months, 85.71% of male participants experienced a 28.42% average increase in hair thickness (sum of hair widths). (*p < 0.05)

- After 6 months, 100% of male participants experienced a 36.68% average increase in hair thickness (sum of hair widths). (***p < 0.001)
Hair cycle

OS-01 HAIR can reactivate the natural hair-growth cycle. (Based on significant increase in anagen hairs.)

OS-01 HAIR significantly increases anagen (growth phase) hairs. (Shown in 73.33% of participants with an average improvement of 42.39% after 6 months)

Shown in 6 month double-blind, independent, third-party clinical study with 30 participants using OS-01 HAIR twice daily and dermarolling once daily. Hair parameters were measured using HairMetrix® clinical photography, Trichoscopy and Phototrichogram.

- After 6 months, 73.33% of participants experienced a 42.39% average increase in anagen hairs per cm2. (***p < 0.001)

- Participants saw a significant increase in anagen hairs per cm2 between 3 and 6 months (*p < 0.05)

6 out of 7 (85.71%) men experienced an average increase of 35.42%% in anagen (growth-phase) hairs within 6 months. 

6 out of 7 (85.71%) men experienced an average increase of 20.19% in anagen (growth-phase) hairs within 3 months.

 

6 out of 7 men had their hair growth cycle return to a healthier state within 3 months. (Base don increase in anagen hairs.)

Shown in 6 month double-blind, independent, third-party clinical study with 7 male participants using OS-01 HAIR twice daily and dermarolling once daily. Hair parameters measured using HairMetrix® clinical photography, Trichoscopy and Phototrichogram.

- After 3 months, 85.71% of male participants experienced a 20.19% average increase in anagen hairs. (*p < 0.05)

- After 6 months, 85.71% of male participants experienced a 35.42% average increase in anagen hairs. (*p < 0.05)
Scalp Microbiome

OS-01 HAIR is clinically validated to support the scalp microbiome.

Clinically shown to support a healthier scalp microbiome by increasing M. globosa abundance, resulting in a lower M. restricta / M. globosa ratio — a key marker associated with reduced dandruff and improved scalp health (Saxena et al., 2018; Ergin et al., 2024)

Shown in a 6-month clinical study performed by a third party research organization (HelloBiome) with 30 participants who collected samples of their scalp microbiome before and after treatment with OS-01 HAIR for 6 months. Using next generation sequencing and existing research, HelloBiome determined that OS-01 HAIR supports skin’s microbiome because:

- Participants displayed significant positive changes in bacterial diversity (significant increase in bacterial diversity, significant decrease in species known to increase with hair loss, and significant increase in species known to decrease with hair loss)

- No significant changes in the fungal diversity were detected after treatment compared to baseline
Consumer perception (clinical study)

3 Months:

80.00% observed improvements in their hair

76.67% observed improvement in the overall health of the hair

70.00% said that existing hair is growing faster

73.33% said that the hair appears fuller

70.00% said that their scalp feels more nourished

6 Months: 

70.00% said existing hair grew faster

76.67% said the overall health of their hair improved

73.33% reported decreased shedding

83.33% said their hair felt nourished

70% reported thicker hair

73.33% reported stronger hair

70% said hair's natural texture was enhanced

Shown in 6 month double-blind, independent, third-party clinical study with 30 participants using OS-01 HAIR twice daily and a dermaroller once daily. Results based on self-perception reporting.
Consumer perception (brand-led study)

Immediately

89.47% agreed they were able to style hair like usual

85% agreed the product is lightweight

2 Months:

80.95% agreed their scalp was more hydrated after 2 months

3 Months:

81.82% noticed new hair growth after 3 months

72.73% saw visibly denser hair (more hairs on their heads) after 3 months

 

 

 Shown in a 3 month beta test (brand led consumer perception study) with 22 participants and daily application (1-2x/day) of OS-01 HAIR (no dermaroller).
Sensitive skin OS-01 HAIR is Dermatologically Tested and Safe for Sensitive Skin. Shown in a clinical study with 55 healthy volunteers by means of repeated cutaneous occlusive patch applications, after which there were no questionable reactions observed.

 

Lab Data

Hair & senescence

OS-01 HAIR is the first scalp serum with the OS-01 peptide, scientifically formulated to target cellular senescence—a biological process linked to hair loss and thinning.

OS-01 HAIR is the first scalp serum with the OS-01 peptide, scientifically formulated to target cellular senescence—a key driver of age-related hair loss & thinning.

Based on lab studies showing that the OS-01 peptide significantly reduces cellular senescence in skin (Zonari, et al, npj Aging, 2023) and that OS-01 HAIR significantly reduces senescence in hair cells (ORSCs).

Shin, Wisoo et al. Dysfunction of Hair Follicle Mesenchymal Progenitors Contributes to Age-Associated Hair Loss. Developmental Cell, 53(2), 185 - 198. 2020
https://www.sciencedirect.com/science/article/pii/S1534580720302318

Mirmirani, Paradi., et al. Age-related hair changes in men: Mechanisms and management of alopecia and graying. Maturitas, 80(1), 58 - 62. 2015.
https://www.sciencedirect.com/science/article/abs/pii/S0378512214003259
Cellular senescence OS-01 HAIR significantly reduces senescence in stressed hair follicle cells.

OS-01 HAIR significantly reduces CRH-induced senescence, suggesting that it may be a potential candidate for addressing stress-induced hair loss.		 Shown in lab studies on ORSCs (hair follicle cells) by measuring the change in senescence via senescence associated-beta galactosidase staining. Cells were treated with corticotropin-releasing hormone (CRH) alone or in combination with OS-01 HAIR. After 72 hours, cells treated with OS-01 HAIR + CRH showed significantly lower senescence levels compared to those treated with CRH alone. (*p < 0.05)
Inflammation OS-01 HAIR significantly reduces a key inflammation biomarker, IL-6, in stressed hair follicle cells. Shown in lab studies on ORSCs (hair follicle cells) by measuring the change in IL-6 via qPCR. Cells were treated with corticotropin-releasing hormone (CRH) alone or in combination with OS-01 HAIR. After 72 hours, cells treated with OS-01 HAIR + CRH showed significantly lower IL-6 levels compared to those treated with CRH alone. (*p < 0.05)